Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Agriculture Fund (DBA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Invesco DB Agriculture FundTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Agriculture Fund vs Neurocrine Biosciences Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.6, while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.

DBANBIX
52-Week High
$28.73$180.55
52-Week Low
$25.44$123.10
Market Cap
$17.30B
Sector
Health
Enterprise Value
$16.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Agriculture Fund

DBA (Invesco DB Agriculture Fund) trades at $27.72, down 0.18% with a bullish technical signal supported by moving averages. The ETF tracks agricultural commodities including corn, soybeans, and livestock. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion U.S. crop purchase commitment through 2028, potentially benefiting agricultural ETFs.

The fund offers exposure to rising commodity prices driven by supply constraints and geopolitical factors, but faces volatility from weather patterns and global demand shifts. Key risks include commodity price fluctuations and concentrated agricultural exposure. Analyst sentiment is mixed with technical indicators showing strength but overbought conditions on shorter-term RSI.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.

NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco DB Agriculture Fund

The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.

Read more on DBA

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX